Characteristics of deaths related to lithium toxicity in Australia, 2000-2024
- PMID: 40292484
- DOI: 10.1177/00048674251336037
Characteristics of deaths related to lithium toxicity in Australia, 2000-2024
Abstract
Objectives: To determine: (1) the characteristics, clinical presentation and circumstances of death for deaths related to lithium toxicity in Australia, 2000-2024; (2) the toxicology of cases; and (3) the major autopsy findings.
Methods: A retrospective study of all cases of death aged ⩾15 years associated with lithium toxicity in Australia, 2000-2024, retrieved from the National Coronial Information System.
Results: We identified 93 cases, with a mean age of 48.7 years (range, 18-89), 12% being aged under 30 years and 51% being male. A diagnosis of bipolar disorder was documented in 52%, with 28% having a documented psychotic disorder. The circumstances of death were unintentional toxicity (58%), intentional toxicity (23%) and undetermined intent (19%). The median blood lithium concentration was 0.68 mmol/L (range, 0.01-17.3). Concentrations were higher for ante-mortem versus post-mortem samples (2.3 vs 0.5 mmol/L), intentional overdose versus unintentional (2.2 vs 0.5 mmol/L) and cases in which lithium was the sole drug detected versus multiple drugs (2.1 vs 0.6 mmol/L). Other drugs were present in the majority (87%), most commonly antipsychotics (67%) and antidepressants (57%). Cardiomegaly was diagnosed in 22% and nephro/arteriosclerosis in 26%.
Discussion: Toxicity remains a rare event compared to exposure to lithium, with intentional cases comprising a fifth of the series. Deaths were not the sole preserve of the middle-aged or elderly.
Keywords: Lithium; mortality; suicide; toxicity; toxicology.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: Shane Darke: None. Johan Duflou: None. Amy Peacock: Funded by a National Health and Medical Research Council Emerging Leadership Investigator Fellowship and has received untied educational grants from Seqirus and Mundipharma for post-marketing surveillance of pharmaceutical opioids. Funding support ceased more than 3 years ago. These organisations had no role in study design, analysis and reporting, and funding support was for work unrelated to this project. Jessy Lim: None. Alys Havard: supported by an NHMRC Ideas grant, NHMRC Medicines Intelligence Centre of Research Excellence. Michael Farrell: has received untied educational grants from Seqirus, Mundipharma and Indivior for post-marketing surveillance of pharmaceutical opioids. These organisations had no role in study design, analysis and reporting, and funding support was for work unrelated to this project. Julia Lappin: None.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical